All In Biotech

Drug Trial Radar · NCT03157128

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)

Last checked: Nov 20, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

857

Actual

Start

May 2, 2017

Primary completion

Feb 14, 2025

Study completion Feb 2027

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
Collaborators
Loxo Oncology, Inc.
First posted
May 17, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.

Conditions

  • Non-Small Cell Lung Cancer
  • Medullary Thyroid Cancer
  • Colon Cancer
  • Any Solid Tumor

Interventions

  • LOXO-292Drug

    Oral LOXO-292

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Maximum Tolerated Dose (MTD)Time frame: Cycle 1 (cycle length = 28 days)
  2. Phase 1: Recommended Phase 2 Dose (RP2D)Time frame: Cycle 1 (cycle length = 28 days)
  3. Phase 2: Objective Response Rate (ORR) Based on Independent Review Committee (IRC) AssessmentTime frame: Approximately for up to 7 years 8 months

Locations

85 sites in 16 countries. Site status is shown where the registry gives one.

  • Mayo Clinic of Scottsdale

    Scottsdale, Arizona

  • City of Hope National Medical Center

    Duarte, California

  • UCLA Medical Center

    Los Angeles, California

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • Kaiser Permanente

    Oakland, California

  • Irvine Medical Center

    Orange, California

  • University of California - San Diego

    San Diego, California

  • UCSF Medical Center at Mission Bay

    San Francisco, California

  • Kaiser Permanente Medical Center

    Walnut Creek, California

  • Sarah Cannon Research Institute at HealthOne

    Denver, Colorado

  • Yale Cancer Center

    New Haven, Connecticut

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • Memorial Hospital Pembroke

    Pembroke, Florida

  • Emory University

    Atlanta, Georgia

  • University of Chicago Medicine-Comprehensive Cancer Center

    Chicago, Illinois

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • University of Maryland Medical Center

    Baltimore, Maryland

  • Johns Hopkins University

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • START Midwest

    Grand Rapids, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University Medical School

    St Louis, Missouri

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Roswell Park Cancer Institute

    Buffalo, New York

  • NYU Langone

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Ohio State University Hospital

    Columbus, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • University of Pennsylvania Hospital

    Philadelphia, Pennsylvania

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Sarah Cannon Research Institute SCRI

    Nashville, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • University of Texas Southwestern Medical Center at Dallas

    Dallas, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • USO-Virginia Cancer Specialists, PC

    Fairfax, Virginia

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.